|
Name |
Ergosterol peroxide
|
Molecular Formula | C28H44O3 | |
IUPAC Name* |
(1S,2R,5R,6R,9R,10R,13S,15S)-5-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-6,10-dimethyl-16,17-dioxapentacyclo[13.2.2.01,9.02,6.010,15]nonadec-18-en-13-ol
|
|
SMILES |
C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@]24C=C[C@@]5([C@@]3(CC[C@@H](C5)O)C)OO4)C
|
|
InChI |
InChI=1S/C28H44O3/c1-18(2)19(3)7-8-20(4)22-9-10-23-25(22,5)13-12-24-26(6)14-11-21(29)17-27(26)15-16-28(23,24)31-30-27/h7-8,15-16,18-24,29H,9-14,17H2,1-6H3/b8-7+/t19-,20+,21-,22+,23+,24+,25+,26+,27+,28-/m0/s1
|
|
InChIKey |
VXOZCESVZIRHCJ-KGHQQZOUSA-N
|
|
Synonyms |
Ergosterol peroxide; Ergosterol endoperoxide; Ergosterol-5,8-peroxide; Peroxyergosterol; 2061-64-5; Ergosterol 5alpha,8alpha-epidioxide; UG9TN81TGH; CHEMBL434750; CHEBI:65858; 5alpha,8alpha-epidioxyergosta-6,22-dien-3beta-ol; NSC31324; NSC-31324; (1S,2R,5R,6R,9R,10R,13S,15S)-5-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-6,10-dimethyl-16,17-dioxapentacyclo[13.2.2.01,9.02,6.010,15]nonadec-18-en-13-ol; 5alpha,8alpha-epidioxy-22E-ergosta-6,22-dien-3beta-ol; (22E,24R)-5alpha,8alpha-epidioxyergosta-6,22-dien-3beta-ol; (24R)-5alpha,8alpha-epidioxy-24-methylcholesta-6,22-dien-3beta-ol; NSC 31324; (3S,5S,8S,9R,10R,13R,14R,17R)-17-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-1,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-2H-5,8-epidioxycyclopenta[a]phenanthren-3-ol; UNII-UG9TN81TGH; (3beta,5alpha,8alpha,22E)-5,8-epidioxyergosta-6,22-dien-3-ol; 5.alpha.,8.alpha.-Ergosta-6,22-dien-3.beta.-ol, 5,8-epidioxy-; Ergosta-6,22-dien-3-ol, 5,8-epidioxy-, (3.beta.,5.alpha.,8.alpha.,22E)-; Ergosterol 5.alpha.,8.alpha.-epidioxide; Ergosterol 5-alpha,8-alpha-epidioxide; BRN 0096852; ERGOSTERYL PEROXIDE; 5-19-03-00043 (Beilstein Handbook Reference); Ergosterol Peroxide_120246; SCHEMBL3281353; ERGOSTEROL 5,8-PEROXIDE; 5,8-Epidioxy-5-alpha,8-alpha-ergosta-6,22-dien-3-beta-ol; DTXSID501021533; HY-N3845; BDBM50334064; ZINC38139718; ERGOSTEROL ENDOPEROXIDE [INCI]; CS-0024320; 5.ALPHA.,8.ALPHA.-EPIDIOXYERGOSTEROL; 5.alpha.,22-dien-3.beta.-ol, 5,8-epidioxy-; 5alpha,8alpha-Epidioxyergosta-6,22-diene-3beta-ol; Q5385831; 5-alpha,8-alpha-ERGOSTA-6,22-DIEN-3-beta-OL, 5,8-EPIDIOXY-; Ergosta-6, 5,8-epidioxy-, (3.beta.,5.alpha.,8.alpha.,22E)-; (22E)-5.ALPHA.,8.ALPHA.-EPIDIOXYERGOSTA-6,22-DIEN-3.BETA.-OL; (24R)-ERGOST-5.ALPHA.,8.ALPHA.-EPIDIOXY-6,22-DIEN-3.BETA.-OL; 3.BETA.-HYDROXY-5.ALPHA.,8.ALPHA.-EPIDIOXYERGOSTA-6,22-DIENE; Ergosta-6,22-dien-3-ol, 5,8-epidioxy-, (3-beta,5-alpha,8-alpha,22E)-; Ergosta-6,22-dien-3-ol, 5,8-epidioxy-, (3beta,5alpha,8alpha,22E)-; (22E,24R)-5.ALPHA.,8.ALPHA.-EPIDIOXYERGOSTA-6,22-DIEN-3.BETA.-OL; 5.ALPHA.,8.ALPHA.-EPIDOXY-(22E,24R)-ERGOSTA-6,22-DIEN-3.BETA.-OL; (1S,2R,5R,6R,9R,10R,13S,15S)-5-[(2R,3E,5R)-5,6-dimethylhept-3-en-2-yl]-6,10-dimethyl-16,17-dioxapentacyclo[13.2.2.0^{1,9}.0^{2,6}.0^{10,15}]nonadec-18-en-13-ol
|
|
CAS | 2061-64-5 | |
PubChem CID | 5351516 | |
ChEMBL ID | CHEMBL434750 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 428.6 | ALogp: | 6.7 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 38.7 | Aromatic Rings: | 6 |
Heavy Atoms: | 31 | QED Weighted: | 0.414 |
Caco-2 Permeability: | -4.849 | MDCK Permeability: | 0.00001820 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.663 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.027 |
30% Bioavailability (F30%): | 0.038 |
Blood-Brain-Barrier Penetration (BBB): | 0.066 | Plasma Protein Binding (PPB): | 90.01% |
Volume Distribution (VD): | 1.146 | Fu: | 2.06% |
CYP1A2-inhibitor: | 0.035 | CYP1A2-substrate: | 0.954 |
CYP2C19-inhibitor: | 0.078 | CYP2C19-substrate: | 0.95 |
CYP2C9-inhibitor: | 0.265 | CYP2C9-substrate: | 0.034 |
CYP2D6-inhibitor: | 0.026 | CYP2D6-substrate: | 0.142 |
CYP3A4-inhibitor: | 0.915 | CYP3A4-substrate: | 0.929 |
Clearance (CL): | 3.268 | Half-life (T1/2): | 0.123 |
hERG Blockers: | 0.78 | Human Hepatotoxicity (H-HT): | 0.891 |
Drug-inuced Liver Injury (DILI): | 0.012 | AMES Toxicity: | 0.003 |
Rat Oral Acute Toxicity: | 0.778 | Maximum Recommended Daily Dose: | 0.985 |
Skin Sensitization: | 0.345 | Carcinogencity: | 0.011 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.047 |
Respiratory Toxicity: | 0.983 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004740 | 1.000 | D0G8OC | 0.431 | ||||
ENC005015 | 1.000 | D06JPB | 0.395 | ||||
ENC005013 | 1.000 | D0G5CF | 0.388 | ||||
ENC005779 | 1.000 | D0Y7LD | 0.341 | ||||
ENC004858 | 0.794 | D0N1TP | 0.302 | ||||
ENC002327 | 0.700 | D01QUS | 0.280 | ||||
ENC004857 | 0.654 | D0G3SH | 0.264 | ||||
ENC005014 | 0.654 | D03ZTE | 0.264 | ||||
ENC004030 | 0.654 | D0M4WA | 0.263 | ||||
ENC006034 | 0.579 | D08SVH | 0.263 |